Dexrazoxane
Acute Lymphoblastic Leukemia, Pediatric
Dana-Farber Cancer InstituteSmall moleculePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 89/ 100
Competitive context
70 Active assets in the Acute Lymphoblastic Leukemia, Pediatric cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BBB |
MERCAPTOPURINE ANHYDROUS Children's Oncology Group | Phase 3 | BBB |
FILGRASTIM St. Jude Children's Research Hospital | Phase 3 | BBB |
METHOTREXATE Children's Oncology Group | Phase 3 | BBB |
Cytosin-Arabinosid Children's Oncology Group | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Dexrazoxane is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
B
Indicative ·
59 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →